Lilly’s Cymbalta helps chronic pain in U.S. review
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta’s
annual sales.
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta’s
annual sales.
Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
Eli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention
deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
The health care industry is responding to reforms that will pay doctors bonuses if they provide high-quality care and save
Medicare money.
Leaders tackle issues ranging from research to cold storage to the future of Eli Lilly and Co.
An experimental medicine for hepatitis C that Lilly helped identify and develop is now on the cusp of market approval, with
analysts predicting as much as $2 billion in annual U.S. sales.
Roche Diagnostics, a Swiss company that keeps its U.S. headquarters in Indianapolis, has been sued for marking its Accu-Chek
blood glucose monitors and accessories with patents that are expired. Illinois resident David O’Neill has sued on behalf
of the U.S. government to recover damages of $500 per infraction.
Proceeds from the sale will be used for working capital and general corporate purposes, including debt repayment, the company
said in a prospectus.
Indianapolis-based health care firm reaches agreement to offer its DailyMed product to more WellPoint Inc. health plan members.
Medicaid Director Pat Casanova says the money will be used for necessary state steps to create an incentive program for medical
providers and hospitals to move from paper records to electronic ones.
Eli Lilly and Co.’s loss of a patent on one of its blockbuster drugs in court late last month received a collective yawn
from
investors, who have shunned the stock because of five looming patent expirations.
The Carmel-based life and health insurer earned $33.1 million in the three months ended June 30, or 12 cents per diluted share.
Excluding losses on investments and retired debt, the company would have earned 16 cents per share.
Arcadia Resources’ DailyMed business will grow revenue 10-fold in the next three years and push the Indianapolis-based
company into profitability, according to a research report by the first analyst to officially cover the company.
Nate Feltman, former state secretary of commerce, has left his partnership position at Baker & Daniels LLP to become president
of Home Health Depot LLP, a
growing home-medical-equipment supplier.
Satori Pointe is being marketed as a campus where medical offices, fitness-oriented retailers and residents would co-exist.
WellPoint Inc., UnitedHealth Group Inc. and three other health insurers, criticized by Democrats during the health care reform
debate, are seeking to influence how the new law will be implemented, and possibly change it, by campaigning for supportive
congressional candidates.
Inquiry stemmed from an article in the New York Times about a dispute between the Warsaw-based maker of artificial hip and knee joints and two of its consultants.
Copenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said.
Ascendis may choose a final bidder by early September.
The Batesville-based maker of hospital beds and furniture announced Wednesday night that it earned $30.6 million in its third quarter, up from $20.2 million in the same quarter of 2009.
The Indianapolis-based insurer of truck and car fleets earned $5 million in the quarter ended June 30, down from $14.2 million
in the same quarter a year ago.